GLP-1 Receptor Agonist Clinical Evidence and FDA Enforcement
Comments Off on GLP-1 Receptor Agonist Clinical Evidence and FDA Enforcement
June 18, 2026
FDA enforcement action GLP-1 highlights critical safety concerns for compounded medications. Clinicians must prioritize FDA-approved receptor agonists for consistent dosing and quality. Understanding these actions supports safer prescribing and patient…
Clinical Evidence on GLP-1 Receptor Agonist Telehealth Transition
Comments Off on Clinical Evidence on GLP-1 Receptor Agonist Telehealth Transition
April 13, 2026
GLP-1 receptor agonist telehealth transition is reshaping patient access to therapies. The phase-out of compounded semaglutide highlights regulatory shifts toward FDA-approved medications. Clinicians must adapt to these changes to ensure continuity of…